For example, NBF-006, a lipid nanoparticle-formulated siRNA targeting the KRAS G12D mutation (present in ~25% of patients with NSCLC), has been evaluated in a Phase I clinical trial (106) for KRAS-mutant NSCLC and pancreatic and colorectal cancer. Here, KRAS is linked to colorectal cancer.